ABEO

NASDAQ Healthcare

Abeona Therapeutics Inc. - Common Stock

Biotechnology

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

�� 市场数据

价格	$5.50
成交量	910,672
市值	313.77M
贝塔系数	1.210
RSI（14日）	81.7 超买
200日均线	$5.44
50日均线	$4.92
52周最高	$7.54
52周最低	$4.00
市盈率	5.45
Forward P/E	22.92
Price / Book	1.90